Cognitive function and social abilities in patients with schizophrenia: Relationship with atypical antipsychotics

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 4, 2006, Pages 473-479

  Tyson, Philip J ^a   Laws, Keith R ^b   Flowers, Kenneth A ^c   Tyson, Agi ^d   Mortimer, Ann M ^c  

^a UNIVERSITY OF GLOUCESTERSHIRE   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

5HT 2A; Atypical antipsychotics; Cognition; Dopamine; Schizophrenia; Serotonin; Social function

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ADJUSTMENT; ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; QUALITY OF LIFE; SCHIZOPHRENIA; SELECTIVE ATTENTION; SOCIAL BEHAVIOR;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; DOPAMINE; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN AGENTS; SOCIAL BEHAVIOR;

EID: 33745957404     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01534.x     Document Type: Article

References (41)

1. Sharma T, Harvey P. Cognitive Deficits in Schizophrenia. Oxford University Press, Oxford, 2000.
2. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr. Bull. 2000; 26: 119-136.
3. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 2000; 45: 175-184.
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996; 153: 321-330.
5. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn KU. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005; 30: 381-390.
6. Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2002; 159: 1018-1028.
7. Good KP, Kiss I, Buiteman C et al. Improvement in cognitive functioning in patients with first episode psychosis after treatment with quetiapine: an interim analysis. Br. J. Psychiatry 2002; 181: s45-s49.
8. Mehta MA, Swainson R, Ogilvie AD, Sahakian J, Robbins TW. Improved short-term spatial memory but impaired reversal learning following the dopamine D (2) agonist bromocriptine in human volunteers. Psychopharmacology (Berl) 2001; 159: 10-20.
9. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and unpaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex.J. Neurosci. 2000;20:1208-1215.
10. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 1999; 146: 162-174.
11. Muller U, von Cramon DY, Pollmann S. D1 versus D2 receptor modulation of visuospatial working memory in humans. J. Neurosci. 1998; 18: 2720-2728.
12. Luciana M, Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb. Cortex 1998; 8: 218-226.
13. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 1997; 8: 3581-3585.
14. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 1997; 17: 8528-8535.
15. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. (Oxf) 1997; 11: 123-131.
16. Jainer AK, Javed MA, Smith AA, Srivastava S. New perspectives in the treatment of schizophrenia. Pak. J. Med. Sci. 2002; 18: 135-144.
17. 3 receptor antagonist with both presynaptic and limbic selectivity. Pharmacol. Exp. Ther. 1997; 280: 83-97.
18. Gerlach J, Peacock L. New antipsychotics: the present status. Int. Clin. Psychopharmacol. 1995; 10: 39-48.
19. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacol. (Oxf) 2004; 174: 17-24.
20. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann. Med. 2000; 32: 210-221.
21. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry 1999; 45: 1-16.
22. Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double blind placebo-controlled study. Eur. Neuropsychopharmacol. 2003; 13: 123-128.
23. Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol. 2001; 21: 479-483.
24. Umbricht D, Vollenweider FX, Schmid L et al. Effects of the 5HT-2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 2003; 28: 170-181.
25. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999; 25: 201-222.
26. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of the atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int. J. Neurosci. 2004; 114: 747-765.
27. Hedlund JL, Vieweg BW. The brief psychiatric rating scale (BPRS): a comprehensive review. J. Oper. Psychiatry 1980; 11: 48-65.
28. Overall JE. The brief psychiatric rating scale in psychopharmacologic research. In: Rockville GW (ed.). ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No (ADM) 76-338). National Institute of Mental Health, USA, 1976; 166-169.
29. Nelson HE. National Adult Reading Test (NART): Test Manual. Nfer Nelson, Windsor, 1982.
30. British Medical Association. British National Formulary. The British Medical Association, London, 2004.
31. Yortson G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatr. Bull. 2000; 24: 130-132.
32. Wechsler D. Wechsler Adult Intelligence Scale-Revised. Psychological Corporation, New York, 1981.
33. Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I. The Test of Everyday Attention. Thames Valley Test Company, Bury St Edmunds, 1994.
34. Wilson BA, Alderman N, Burgess PW, Emslie H, Evans JJ. Behavioural Assessment of the Dysexecutive Syndrome. Thames Valley Test Company, Bury St Edmunds, 1996.
35. Barker S, Barron N, McFarland BH, Bigelow DA. A community ability scale for chronically mentally ill consumers: Part 1 Reliability and validity. Community Ment. Health J. 1994; 30: 363-383.
36. Skantze K, Malm U. A new approach to facilitation of working alliances based on patients' quality of life goals. Nord. J. Psychiatry 1994; 48: 37-49.
37. Meneses A. 5-HT system and cognition. Neurosci. Biobehav. Rev. 1999; 23: 1111-1125.
38. Steckler T, Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav. Brain Res. 1995; 67: 165-199.
39. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 2004; 174: 45-53.
40. Robbins TW, Everitt BJ. Arousal systems and attention. In: Gazzaniga M (ed.). The Cognitive Neurosciences. MIT Press, Cambridge, MA, 1995; 703-720.
41. Taylor D, McConnell H, McConnell D, Kerwin R. The Maudsley Prescribing Guidelines, 6th edn. Martin Dunitz, London, 2001.